- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850730
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Nicole Schaefer
- Phone Number: 410-357-9932
- Email: nicole.schaefer@curehht.org
Study Contact Backup
- Name: Dennis L Sprecher, MD
- Phone Number: 410-357-9932
- Email: dennis.sprecher@curehht.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
a definite diagnosis of hereditary hemorrhagic telangiectasia defined as having at least 3 of the following criteria:
- Spontaneous and recurrent epistaxis.
- Multiple telangiectasias at characteristic sites: lips, oral cavity, fingers, nose.
- Visceral lesions: GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs.
- A first degree relative with hereditary hemorrhagic telangiectasia according to these criteria.
OR a gene sequencing diagnosis of hereditary hemorrhagic telangiectasia
2. Epistaxis due to hereditary hemorrhagic telangiectasia at least 2x per week, for a cumulative duration of at least 25 minutes per week
3. Epistaxis is clinically stable during the 12 weeks prior to screening in the clinical judgment of the investigator (i.e. no major changes in frequency or duration of epistaxis).
4. Participant agrees not to undergo cautery of nasal telangiectasias or take any experimental therapies for hereditary hemorrhagic telangiectasia other than the study drug while participating in the study.
5. Male or female [non-child bearing potential]
Exclusion Criteria:
- Participant has known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib that in the opinion of the investigator contradicts their participation.
- Currently has untreated cerebral arterio-venous malformations (AVMs), cerebral arteriovenous fistulae, or cerebral cavernous malformations (CCMs) (Note: MRI scan does not need to be repeated at screening if AVMs, arterio-venous fistulas and CCMs were absent on a scan at age ≥18 years).
- Currently has perfused pulmonary AVMs with feeding artery diameter >3mm.
- Known significant bleeding sources other than nasal or gastrointestinal.
- Systemic use of a vascular endothelial growth factor inhibitor in the past 3 months or previous enrollment in this study.
- Active and recent onset of clinically significant diarrhea.
- Current or recent (in the last 5 years) malignancies (except non-melanoma skin cancers)
- Participant has had major surgery (e.g. surgical ligation of an AVM) or trauma within 28 days or had minor surgical procedures (e.g. central venous access line removal) within 7 days prior to dosing, the latter representing a recent wound, fracture or ulcer
- Participant has a planned surgery during the period to include active treatment and 6 weeks of follow up.
- Participant has clinically significant gastrointestinal abnormalities (other than hereditary hemorrhagic telangiectasia related vascular lesions)
- Participant during the 6 months prior to first dose of study drug has a history of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism, untreated deep vein thrombosis (DVT), myocardial infarction, or any other thrombotic event.
- QTc ≥450 msec, based on averaged QTc values of triplicate ECGs obtained over a brief recording period [The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. The same QT correction formula must be used for each individual participant to determine eligibility for and withdrawal from the study.]
- Hgb <6 g/dL.
- Platelets < 100x109/L.
- International normalized ratio (INR) >1.2x upper limit of normal and activated partial thromboplastin time (aPTT)>1.2x upper limit of normal.
- Alanine Transaminase >2x upper limit of normal.
- Bilirubin >1.5x upper limit of normal (isolated bilirubin >1.5x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Participant has poorly controlled hypertension [defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry [between screen and baseline]. At Screening, blood pressure must be assessed three times and the mean SBP/DBP must be <140/90 mmHg in order for a participant to be eligible for the study.]
- Substantive renal disease (eGFR <30 mL/min/1.73m2calculated using the Cockcroft-Gault formula)
- Echo derived left ventricular ejection fraction <30%.
- Thyroid stimulating hormone > upper limit of normal.
- Urine protein to creatinine ratio >0.3.
- Neutrophil count <1500/mm3.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pazopanib
Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline.
If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
|
Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in epistaxis duration in minutes
Time Frame: Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing
|
A daily electronic record of each bleed, with start and end time, provides the daily epistaxis duration, compounded over each 3 weeks of study time
|
Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in average gushing frequency
Time Frame: Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing
|
Patient rated intensity of each bleed, as in 0 or 1, averaged over 3 wk periods.
|
Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing
|
Percent change in average bleed frequency
Time Frame: Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing
|
Annotated number of bleeds per day, and summed over 3 week periods
|
Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing
|
Absolute [gm/dl] change in serum hemoglobin
Time Frame: comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing
|
Serum values drawn every 3 weeks
|
comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing
|
Change in the frequency of blood transfusions
Time Frame: Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing
|
Use of packed red blood cells over 6 week time periods.
|
Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing
|
Change in the frequency of IV iron infusions
Time Frame: Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration
|
Number of interval IV iron infusions in 6 week periods
|
Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration
|
Percent change in the per bleed average epistaxis severity
Time Frame: The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study
|
Epistaxis severity score [0-10] housed in the current patient reported outcome instrument will be averaged
|
The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study
|
Daily monitoring for change in systolic blood pressure [mm mercury] using daily recordings
Time Frame: Daily from baseline through up to 24 weeks till on-drug study completion.
|
Patients rising above 140 mm mercury, or those who increase by 20 or more mm mercury will trigger protocol defined treatments.
|
Daily from baseline through up to 24 weeks till on-drug study completion.
|
Daily monitoring for change in diastolic blood pressure [mm mercury]
Time Frame: Daily from baseline through up to 24 weeks till on-drug study completion
|
Patients rising above 90 mm mercury, or those who increase by 10 mm mercury or more will trigger protocol defined treatments.
|
Daily from baseline through up to 24 weeks till on-drug study completion
|
Number of participants with changes in alanine aminotransferase [liver function test]
Time Frame: Baseline and throughout the 16-24 week dosing period
|
measurement every 3 weeks to evaluate fold increase with use of drug
|
Baseline and throughout the 16-24 week dosing period
|
Monitor for active and safe trough serum drug concentrations
Time Frame: Over 16-24 week duration of study; once at steady state for each administered dose
|
Assays to be analyzed to evaluate the exposures done to remain within safe and effective range [1ug/ ml to 10ug/ml].....
|
Over 16-24 week duration of study; once at steady state for each administered dose
|
Evaluate for change in composite mental quality of life scores
Time Frame: baseline, week 12 and at study drug-dosing end; 16, 20 or 24weeks
|
short form health survey 36 [range 1-100, higher number representing better self-reported mental health]
|
baseline, week 12 and at study drug-dosing end; 16, 20 or 24weeks
|
Evaluate for change in composite physical quality of life scores
Time Frame: baseline, week 12 and at study drug-dosing end; up to 24 weeks.
|
short form health survey 36 [range 1-100, higher number representing better self-reported physical health]
|
baseline, week 12 and at study drug-dosing end; up to 24 weeks.
|
Evaluate for change in fatigue composite scores
Time Frame: baseline and study end; up to 24 weeks
|
Patient-report outcome measurement information system-fatigue; [0-100 scale; lower number representing less fatigue].
Queries the degree of fatigue and the implications on physical functioning.
Reduction of 5 or more in the composite score represents clinically relevant reductions in fatigue.
|
baseline and study end; up to 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interrogate levels of Iron stores
Time Frame: baseline and at on-drug study end; 16, 20 or 24 weeks depending on study duration
|
Ferritin serum levels [normal range 12 ug/ ml to 150ug/ml female, 300ug/ ml male].
However, above 30ug/ ml valued as relevant for proper erythropoiesis]
|
baseline and at on-drug study end; 16, 20 or 24 weeks depending on study duration
|
Characterize change in left ventricular stress
Time Frame: baseline and on-drug study end; 16, 20 or 24 weeks depending on study duration]
|
NTproBNP serum values represent a surrogate for left ventricular stress [<125pg/ml normal, while above 350pg/ml high and potentially consistent with heart failure]
|
baseline and on-drug study end; 16, 20 or 24 weeks depending on study duration]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Raj Kasthuri, MD, University of North Carolina
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Otorhinolaryngologic Diseases
- Hemostatic Disorders
- Signs and Symptoms, Respiratory
- Nose Diseases
- Cardiovascular Abnormalities
- Vascular Malformations
- Epistaxis
- Telangiectasis
- Telangiectasia, Hereditary Hemorrhagic
Other Study ID Numbers
- HT3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epistaxis
-
NasaClipEmergency Medical Innovations, LLCRecruiting
-
Bezmialem Vakif UniversityCompleted
-
Izmir Ataturk Training and Research HospitalCompletedTranexamic Acid | Anterior EpistaxisTurkey
-
University of ZurichCompletedNosebleed (Epistaxis) - Posterior or AnteriorSwitzerland
-
University Hospital, Strasbourg, FranceRecruitingEpistaxis, Anterior Ethmoid ArteryFrance
-
Buddhist Tzu Chi General HospitalUnknownInjury Due to Endoscopic Examination | Transnasal Endoscopy Induced Epistaxis | Transnasal Endoscopy Induced Nasal PainTaiwan
-
University of AlbertaCompleted
-
Combined Military Hospital, PakistanCompleted
-
University of British ColumbiaCompleted
Clinical Trials on Pazopanib
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedMetastatic Renal Cell Carcinoma
-
Institut Claudius RegaudNovartisTerminatedMetastatic Cancer (Different Solid Tumour Types)France
-
Gynecologic Oncology GroupGlaxoSmithKlineWithdrawnUterine Leiomyosarcoma
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Spanish Oncology Genito-Urinary GroupCompletedMetastatic Renal Cell CarcinomaSpain
-
GlaxoSmithKlineCompletedMacular DegenerationUnited States
-
Samsung Medical CenterCompletedLocally Advanced or Metastatic Non-clear Cell Type Renal Cell CarcinomaKorea, Republic of
-
Samsung Medical CenterCompletedNeuroendocrine TumorKorea, Republic of
-
Novartis PharmaceuticalsCompletedMetastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaSpain, Germany, United States, Austria, Czechia, United Kingdom, Argentina, Hungary, France, Canada, Chile